Sanofi (SNY) Stock Forecast, Price Target & Predictions
SNY Stock Forecast
Sanofi stock forecast is as follows: an average price target of $57.36 (represents a 8.33% upside from SNY’s last price of $52.95) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
SNY Price Target
The average price target for Sanofi (SNY) is $57.36 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $64.00 to $48.07. This represents a potential 8.33% upside from SNY's last price of $52.95.
SNY Analyst Ratings
According to 7 Wall Street analysts, Sanofi's rating consensus is 'Buy'. The analyst rating breakdown for SNY stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 0 'Hold' (0.00%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).
Sanofi Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | Luisa Hector | Berenberg Bank | $64.00 | $58.51 | 9.38% | 20.87% |
| Jul 26, 2024 | Jasper Hellweg | Argus Research | $60.00 | $52.53 | 14.21% | 13.31% |
| Apr 03, 2024 | Jasper Hellweg | Argus Research | $55.00 | $48.00 | 14.58% | 3.87% |
| Dec 21, 2022 | Iain Simpson | Barclays | $48.07 | $48.17 | -0.21% | -9.22% |
The latest Sanofi stock forecast, released on Sep 10, 2024 by Luisa Hector from Berenberg Bank, set a price target of $64.00, which represents a 9.38% increase from the stock price at the time of the forecast ($58.51), and a 20.87% increase from SNY last price ($52.95).
Sanofi Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $64.00 | $59.67 |
| Last Closing Price | $52.95 | $52.95 | $52.95 |
| Upside/Downside | -100.00% | 20.87% | 12.69% |
In the current month, the average price target of Sanofi stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Sanofi's last price of $52.95. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 10, 2024 | Deutsche Bank | Sell | Sell | Hold |
| Sep 23, 2024 | Barclays | Overweight | Overweight | Hold |
| Sep 17, 2024 | Citigroup | Buy | Buy | Hold |
| Jul 29, 2024 | Deutsche Bank | Sell | Sell | Hold |
| Jul 11, 2024 | Guggenheim | Buy | Buy | Hold |
| Jul 02, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 18, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 12, 2022 | Deutsche Bank | - | Hold | Upgrade |
| Jun 07, 2022 | UBS | Buy | Buy | Hold |
Sanofi's last stock rating was published by Deutsche Bank on Oct 10, 2024. The company gave SNY a "Sell" rating, the same as its previous rate.
Sanofi Financial Forecast
Sanofi Revenue Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Jun 21 | Jun 20 | Mar 19 | Jun 18 | Mar 17 | Mar 16 | Sep 15 | Dec 13 | Sep 12 | Sep 11 | Dec 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $10.86B | $11.46B | $10.05B | $9.04B | $8.44B | $8.71B | $8.48B | $8.90B | $7.93B | $9.68B | $8.54B | $9.24B | $9.17B | $7.73B | $7.09B | $7.06B | $7.32B | $6.66B |
| Avg Forecast | $11.50B | $12.22B | $13.15B | $10.85B | $10.62B | $11.93B | $12.48B | $11.03B | $12.73B | $10.03B | $10.54B | $7.72B | $8.02B | $8.25B | $8.26B | $8.24B | $9.46B | $10.88B | $12.08B | $8.79B | $10.50B | $11.52B | $5.76B | $6.57B | $6.15B |
| High Forecast | $11.78B | $12.80B | $13.47B | $11.11B | $10.88B | $12.33B | $12.69B | $13.24B | $15.28B | $12.03B | $12.64B | $9.27B | $9.62B | $9.89B | $9.91B | $9.88B | $11.35B | $13.06B | $14.50B | $10.55B | $12.60B | $13.83B | $6.91B | $7.89B | $7.37B |
| Low Forecast | $11.12B | $11.45B | $12.47B | $10.49B | $10.27B | $11.58B | $12.25B | $8.82B | $10.19B | $8.02B | $8.43B | $6.18B | $6.41B | $6.60B | $6.61B | $6.59B | $7.57B | $8.71B | $9.67B | $7.03B | $8.40B | $9.22B | $4.61B | $5.26B | $4.92B |
| # Analysts | 1 | 4 | 5 | 4 | 1 | 3 | 5 | 16 | 20 | 9 | 10 | 16 | 14 | 12 | 9 | 12 | 16 | 7 | 17 | 12 | 19 | 17 | 13 | 16 | 9 |
| Surprise % | - | - | - | - | - | - | - | 0.98% | 0.90% | 1.00% | 0.86% | 1.09% | 1.09% | 1.03% | 1.08% | 0.96% | 1.02% | 0.79% | 0.76% | 1.04% | 0.74% | 0.62% | 1.23% | 1.11% | 1.08% |
Sanofi's average Quarter revenue forecast for Sep 23 based on 5 analysts is $12.48B, with a low forecast of $12.25B, and a high forecast of $12.69B. SNY's average Quarter revenue forecast represents a 14.90% increase compared to the company's last Quarter revenue of $10.86B (Mar 23).
Sanofi EBITDA Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Jun 21 | Jun 20 | Mar 19 | Jun 18 | Mar 17 | Mar 16 | Sep 15 | Dec 13 | Sep 12 | Sep 11 | Dec 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 4 | 5 | 4 | 1 | 3 | 5 | 16 | 20 | 9 | 10 | 16 | 14 | 12 | 9 | 12 | 16 | 7 | 17 | 12 | 19 | 17 | 13 | 16 | 9 |
| EBITDA | - | - | - | - | - | - | - | $3.38B | $2.71B | $3.03B | $1.99B | $8.68B | $2.06B | $1.52B | $6.65B | $1.78B | $2.63B | $2.02B | $3.00B | $3.38B | $2.29B | $2.02B | $1.33B | $2.96B | $2.09B |
| Avg Forecast | $3.87B | $4.11B | $4.42B | $3.65B | $2.93B | $4.01B | $4.20B | $2.66B | $2.02B | $2.42B | $1.89B | $2.60B | $1.89B | $1.48B | $6.18B | $1.85B | $2.57B | $2.58B | $3.92B | $3.25B | $3.12B | $3.28B | $1.09B | $2.66B | $1.93B |
| High Forecast | $3.96B | $4.30B | $4.53B | $3.74B | $3.51B | $4.15B | $4.27B | $3.19B | $2.42B | $2.90B | $2.26B | $3.12B | $2.27B | $1.77B | $7.41B | $2.22B | $3.08B | $3.09B | $4.70B | $3.89B | $3.74B | $3.94B | $1.30B | $3.19B | $2.32B |
| Low Forecast | $3.74B | $3.85B | $4.19B | $3.53B | $2.34B | $3.90B | $4.12B | $2.13B | $1.62B | $1.93B | $1.51B | $2.08B | $1.51B | $1.18B | $4.94B | $1.48B | $2.05B | $2.06B | $3.14B | $2.60B | $2.49B | $2.62B | $869.91M | $2.13B | $1.54B |
| Surprise % | - | - | - | - | - | - | - | 1.27% | 1.34% | 1.25% | 1.05% | 3.34% | 1.09% | 1.03% | 1.08% | 0.96% | 1.02% | 0.79% | 0.76% | 1.04% | 0.74% | 0.62% | 1.23% | 1.11% | 1.08% |
5 analysts predict SNY's average Quarter EBITDA for Sep 23 to be $4.20B, with a high of $4.27B and a low of $4.12B. This is 24.06% upper than Sanofi's previous annual EBITDA (Mar 23) of $3.38B.
Sanofi Net Income Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Jun 21 | Jun 20 | Mar 19 | Jun 18 | Mar 17 | Mar 16 | Sep 15 | Dec 13 | Sep 12 | Sep 11 | Dec 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 4 | 5 | 4 | 1 | 3 | 5 | 16 | 20 | 9 | 10 | 16 | 14 | 12 | 9 | 12 | 16 | 7 | 17 | 12 | 19 | 17 | 13 | 16 | 9 |
| Net Income | - | - | - | - | - | - | - | $2.00B | $1.46B | $2.01B | $1.21B | $7.60B | $1.14B | $762.00M | $5.70B | $1.09B | $1.63B | $1.06B | $1.54B | $2.03B | $1.21B | $1.17B | $1.33B | $1.51B | $1.41B |
| Avg Forecast | $2.49B | $2.08B | $3.11B | $2.08B | $2.04B | $2.15B | $3.25B | $1.86B | $1.19B | $1.69B | $1.15B | $6.90B | $1.05B | $740.83M | $5.29B | $1.13B | $1.59B | $1.34B | $2.01B | $1.95B | $1.64B | $1.89B | $1.09B | $1.36B | $1.31B |
| High Forecast | $2.57B | $2.22B | $3.21B | $2.14B | $2.45B | $2.43B | $4.08B | $2.23B | $1.43B | $2.03B | $1.38B | $8.28B | $1.26B | $889.00M | $6.35B | $1.36B | $1.91B | $1.61B | $2.42B | $2.34B | $1.97B | $2.27B | $1.30B | $1.63B | $1.57B |
| Low Forecast | $2.39B | $1.90B | $2.98B | $1.99B | $1.63B | $2.04B | $1.97B | $1.49B | $955.99M | $1.35B | $918.99M | $5.52B | $836.83M | $592.67M | $4.24B | $903.48M | $1.27B | $1.08B | $1.61B | $1.56B | $1.31B | $1.52B | $869.91M | $1.09B | $1.04B |
| Surprise % | - | - | - | - | - | - | - | 1.07% | 1.22% | 1.19% | 1.05% | 1.10% | 1.09% | 1.03% | 1.08% | 0.96% | 1.02% | 0.79% | 0.76% | 1.04% | 0.74% | 0.62% | 1.23% | 1.11% | 1.08% |
Sanofi's average Quarter net income forecast for Sep 23 is $3.25B, with a range of $1.97B to $4.08B. SNY's average Quarter net income forecast represents a 62.89% increase compared to the company's last Quarter net income of $2.00B (Mar 23).
Sanofi SG&A Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Jun 21 | Jun 20 | Mar 19 | Jun 18 | Mar 17 | Mar 16 | Sep 15 | Dec 13 | Sep 12 | Sep 11 | Dec 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 4 | 5 | 4 | 1 | 3 | 5 | 16 | 20 | 9 | 10 | 16 | 14 | 12 | 9 | 12 | 16 | 7 | 17 | 12 | 19 | 17 | 13 | 16 | 9 |
| SG&A | - | - | - | - | - | - | - | $2.61B | $2.90B | $2.38B | $2.34B | $2.27B | $2.38B | $2.51B | $2.48B | $2.21B | $2.46B | $2.15B | $2.18B | $2.11B | $1.99B | $1.78B | - | - | - |
| Avg Forecast | $2.84B | $3.02B | $3.25B | $2.68B | $2.42B | $2.95B | $3.08B | $2.20B | $2.91B | $2.00B | $2.22B | $2.06B | $2.19B | $2.44B | $2.30B | $2.30B | $2.41B | $2.74B | $2.85B | $2.03B | $2.71B | $2.90B | $1.42B | $1.62B | $1.52B |
| High Forecast | $2.91B | $3.16B | $3.33B | $2.74B | $2.90B | $3.05B | $3.14B | $2.64B | $3.50B | $2.40B | $2.66B | $2.47B | $2.62B | $2.92B | $2.76B | $2.76B | $2.89B | $3.28B | $3.41B | $2.43B | $3.25B | $3.47B | $1.71B | $1.95B | $1.82B |
| Low Forecast | $2.75B | $2.83B | $3.08B | $2.59B | $1.94B | $2.86B | $3.03B | $1.76B | $2.33B | $1.60B | $1.77B | $1.64B | $1.75B | $1.95B | $1.84B | $1.84B | $1.92B | $2.19B | $2.28B | $1.62B | $2.16B | $2.32B | $1.14B | $1.30B | $1.21B |
| Surprise % | - | - | - | - | - | - | - | 1.19% | 0.99% | 1.19% | 1.05% | 1.10% | 1.09% | 1.03% | 1.08% | 0.96% | 1.02% | 0.79% | 0.76% | 1.04% | 0.74% | 0.62% | - | - | - |
Sanofi's average Quarter SG&A projection for Sep 23 is $3.08B, based on 5 Wall Street analysts, with a range of $3.03B to $3.14B. The forecast indicates a 18.25% rise compared to SNY last annual SG&A of $2.61B (Mar 23).
Sanofi EPS Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Jun 21 | Jun 20 | Mar 19 | Jun 18 | Mar 17 | Mar 16 | Sep 15 | Dec 13 | Sep 12 | Sep 11 | Dec 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 4 | 5 | 4 | 1 | 3 | 5 | 16 | 20 | 9 | 10 | 16 | 14 | 12 | 9 | 12 | 16 | 7 | 17 | 12 | 19 | 17 | 13 | 16 | 9 |
| EPS | - | - | - | - | - | - | - | $0.80 | $0.58 | $0.81 | $0.48 | $3.03 | $0.46 | $0.31 | $2.26 | $0.42 | $0.63 | $0.40 | $0.58 | $0.76 | $0.46 | $0.44 | $0.49 | $0.56 | $0.53 |
| Avg Forecast | $1.00 | $0.83 | $1.25 | $0.83 | $0.86 | $0.86 | $1.30 | $0.80 | $0.74 | $0.71 | $0.63 | $0.52 | $0.61 | $0.60 | $0.61 | $0.70 | $0.77 | $1.23 | $1.95 | $0.86 | $1.95 | $5.61 | $0.53 | $0.65 | $0.46 |
| High Forecast | $1.03 | $0.89 | $1.29 | $0.86 | $0.89 | $0.97 | $1.64 | $0.97 | $0.90 | $0.86 | $0.76 | $0.63 | $0.74 | $0.72 | $0.73 | $0.84 | $0.92 | $1.48 | $2.33 | $1.03 | $2.34 | $6.73 | $0.64 | $0.79 | $0.56 |
| Low Forecast | $0.96 | $0.76 | $1.19 | $0.80 | $0.82 | $0.82 | $0.79 | $0.63 | $0.59 | $0.57 | $0.51 | $0.42 | $0.49 | $0.48 | $0.49 | $0.56 | $0.62 | $0.98 | $1.56 | $0.69 | $1.56 | $4.48 | $0.43 | $0.52 | $0.37 |
| Surprise % | - | - | - | - | - | - | - | 1.00% | 0.78% | 1.14% | 0.77% | 5.79% | 0.74% | 0.51% | 3.73% | 0.60% | 0.81% | 0.33% | 0.30% | 0.88% | 0.24% | 0.08% | 0.93% | 0.86% | 1.14% |
According to 5 Wall Street analysts, Sanofi's projected average Quarter EPS for Sep 23 is $1.30, with a low estimate of $0.79 and a high estimate of $1.64. This represents a 62.64% increase compared to SNY previous annual EPS of $0.80 (Mar 23).
Sanofi Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GSK | GSK | $36.97 | $58.00 | 56.88% | Hold |
| MRK | Merck | $101.87 | $129.47 | 27.09% | Buy |
| AZN | AstraZeneca | $71.43 | $84.33 | 18.06% | Buy |
| BMY | Bristol-Myers Squibb Company | $55.45 | $64.57 | 16.45% | Hold |
| JNJ | Johnson & Johnson | $158.24 | $179.13 | 13.20% | Buy |
| SNY | Sanofi | $52.95 | $57.36 | 8.33% | Buy |
| NVS | Novartis | $110.52 | $116.33 | 5.26% | Hold |
| AMGN | Amgen | $316.91 | $293.15 | -7.50% | Buy |
| GILD | Gilead Sciences | $89.84 | $81.32 | -9.48% | Buy |
| ABBV | AbbVie | $200.47 | $174.04 | -13.18% | Buy |
SNY Forecast FAQ
Is Sanofi a good buy?
Yes, according to 7 Wall Street analysts, Sanofi (SNY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of SNY's total ratings.
What is SNY's price target?
Sanofi (SNY) average price target is $57.36 with a range of $48.07 to $64, implying a 8.33% from its last price of $52.95. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Sanofi stock go up soon?
According to Wall Street analysts' prediction for SNY stock, the company can go up by 8.33% (from the last price of $52.95 to the average price target of $57.36), up by 20.87% based on the highest stock price target, and down by -9.22% based on the lowest stock price target.
Can Sanofi stock reach $80?
SNY's average twelve months analyst stock price target of $57.36 does not support the claim that Sanofi can reach $80 in the near future.
What are Sanofi's analysts' financial forecasts?
Sanofi's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $35.44B (high $38.26B, low $32.66B), average EBITDA is $10.87B (high $11.61B, low $10.14B), average net income is $7.26B (high $8.74B, low $5.49B), average SG&A $8.23B (high $8.82B, low $7.65B), and average EPS is $2.96 (high $3.57, low $2.24). SNY's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $46.84B (high $48.26B, low $44.67B), average EBITDA is $15.11B (high $16.08B, low $13.91B), average net income is $9.32B (high $10.03B, low $8.5B), average SG&A $11.37B (high $12.14B, low $10.43B), and average EPS is $3.77 (high $3.92, low $3.57).
Did the SNY's actual financial results beat the analysts' financial forecasts?
Based on Sanofi's last annual report (Dec 2022), the company's revenue was $45.39B, beating the average analysts forecast of $22.76B by 99.44%. Apple's EBITDA was $13.77B, beating the average prediction of $4.44B by 210.21%. The company's net income was $6.72B, beating the average estimation of $2.88B by 133.06%. Apple's SG&A was $10.49B, beating the average forecast of $4.91B by 113.54%. Lastly, the company's EPS was $3.35, beating the average prediction of $1.46 by 129.92%. In terms of the last quarterly report (Mar 2023), Sanofi's revenue was $10.86B, missing the average analysts' forecast of $11.03B by -1.51%. The company's EBITDA was $3.38B, beating the average prediction of $2.66B by 27.15%. Sanofi's net income was $2B, beating the average estimation of $1.86B by 7.42%. The company's SG&A was $2.61B, beating the average forecast of $2.2B by 18.54%. Lastly, the company's EPS was $0.8, missing the average prediction of $0.8 by -0.00%